Overview

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
Purpose:1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To evaluate the effect of DH001 on the efficacy of doxorubicin treatment in cancer patients 4.To evaluate the safety of DH001 in cancer patients treated with doxorubicin
Phase:
Phase 2
Details
Lead Sponsor:
Monyan Pharmaceutical (Shanghai) Co., Ltd.